Keryx Biopharmaceuticals Inc.

Mr. Bentsur has served as Keryx's Chief Executive Officer since May 2009. Prior to joining Keryx, Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals, Inc. ("XTL"), a position he held from January 2006 until April 2009. Prior to his tenure at XTL, Mr. Bentsur was with Keryx from 2000-2006, serving as our Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/ biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr. Bentsur worked as an investment banker in NYC, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA, Magna Cum Laude, from New York University's Stern Graduate School of Business.

Craig Henderson, M.D. is one of the world's leading breast cancer clinicians and researchers. He is currently President of Keryx Biopharmaceuticals and on the Board of Directors of ALZA Corporation. He is also Adjunct Professor, in the Department of Hematology/Oncology at the University of California, San Francisco. Previously, he was a member of the Harvard faculty for 18 years before moving to the University of California, San Francisco where he was Professor of Medicine, Chief of Hematology/Oncology, and Associate Director of the Cancer Center. In 1995, he became Chief Executive Officer and Chairman of SEQUUS Pharmaceuticals, Inc., Menlo Park, California, and continued there until the merger with ALZA Corporation in 1999. SEQUUS Pharmaceuticals was a drug delivery company with an expertise in developing and marketing anti-cancer drugs. Among Dr. Henderson's many appointments, Dr. Henderson served as a member of the FDA Oncologic Drugs Advisory Committee and was the chairman of such committee from 1990-1992.

Mr. Oliviero has served as Keryx's Vice President, Finance since March 2008. From May 2003 until March 2008, Mr. Oliviero served as Keryx's Controller, where he was involved in all capital raising, licensing and acquisition transactions. Since joining Keryx, Mr. Oliviero has also been in charge of leading Keryx's efforts to comply with Securities and Exchange Commission rules and regulations and other corporate governance matters. From August 1999 until May 2003, Mr. Oliviero served as Director of Finance for ACCESS Oncology, Inc., a privately-held biotechnology company. From July 1997 to August 1999, Mr. Oliviero was an investment banker at ING Barings Furman Selz in New York City, where he worked on various mergers and acquisitions and equity and debt transactions. Mr. Oliviero holds a B.B.A. in Finance with Highest Distinction from Emory University's Goizueta Business School.

Mr. Kash is a co-founder and Chairman of Two River Group. Prior to co-founding Two River, from June 1992 until September 2004, Mr. Kash was Senior Managing Director of Paramount BioCapital Investments, LLC, as well as Paramount BioCapital, Inc. (collectively, "Paramount"), an NASD member broker dealer specializing in conducting private financings for public and private development stage biotechnology companies. Mr. Kash has raised more than $500 million in private equity financings for more than 20 biopharmaceutical companies. He has also served on the board of directors of several privately held and publicly traded biotechnology companies, including as vice chairman of the Board of Directors of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) and Javelin Pharmaceuticals, Inc. (OTCBB:JVPH.OB). He has also served as a director of several offshore investment vehicles. Mr. Kash served as an Associate Professor of Marketing at Polytechnic University and was an Adjunct Professor of Entrepreneurship and International Venture Capital at the Wharton School of Business at the University of Pennsylvania from 1996-2000. He was Entrepreneur in Residence at Pace University Spring 2001 and at Ball State University in May 2002. He served as a Visiting Professor of Entrepreneurship at the Graduate School of Business at Nihon University in Tokyo. Currently, he is an Adjunct Professor of Entrepreneurship at the Sy Syms School of Business. Mr. Kash earned his B.S. in Management Science from SUNY Binghamton and his M.B.A. in Banking and International Finance from Pace University. He serves on the Board of Keren-Or, a charity for blind and multi-handicapped children. In 2001 Mr. Kash published his book, Make Your Own Luck (Prentice Hall), which has since been translated into five languages.

"I was just expecting funding and received in addition a lot of experience, wisdom and a global support that does not ignore personal issues. All that makes JGV our home-base." Prof Ben-Sasson, a world-renowned cell biologist, leads Chiasma's research. Muli is an Associate Professor at the Department of Experimental Medicine and Cancer Research, Hebrew University-Hadassah Medical School, Jerusalem, former Chairman of the Hubert H. Humphrey Center for Experimental Medicine and Cancer Research there. He also holds a position of visiting professor at the Harvard Medical School. Muli is an experienced life sciences entrepreneur, with over 20 patents registered to his name. He is scientific founder of Keryx Biopharmaceuticals Inc. (NASDAQ KERX) and the inventor of its KinAce core technology that enables a rational drug design vis-a-vis a broad spectrum of protein kinases.

Array

Dr. Rose is executive vice president for life sciences at MacAndrews & Forbes Holdings and CEO of Siga Technologies, Inc. He is also an active member of the National Biodefense Science Board (NBSB). Dr. Rose is currently on leave as professor and chairman of the Department of Surgery at Columbia University College of Physicians and Surgeons. He pioneered heart transplantation in children, performing the first successful pediatric heart transplant and has investigated alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. Dr. Rose is a past President of the International Society for Heart and Lung Transplantation. Dr. Rose is also Morris & Rose Millstein Professor of Surgery at Columbia University's College of Physicians and Surgeons' Department of Surgery. Dr. Rose also serves as a Director of Abiomed, Inc., Nephros, Inc. and Keryx Biopharmaceuticals, Inc. Dr. Rose is a graduate of both Columbia College and the Columbia University College of Physicians & Surgeons.

Jack Kaye, 64, has served on our Board of Directors since September 2006. Mr. Kaye began his career at Deloitte & Touche, LLP, an international accounting, tax and consulting firm, in 1970, and was a partner in the firm from 1978 until May 2006, when he retired. At Deloitte, Mr. Kaye was responsible for serving a diverse client base of public and private, global and domestic, companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/Sarbanes-Oxley issues. In addition, he has served as Deloitte s Tri-state liaison with the banking and finance community and assisted clients with numerous merger and acquisition transactions. Most recently, Mr. Kaye served as Partner-in-Charge of Deloitte s Tri-State Core Client practice, a position he held for more than twenty years. Mr. Kaye also serves on the board of directors of Balboa Biosciences, Inc., a privately owned biotech company. Mr. Kaye earned a B.B.A. from Baruch College and is a Certified Public Accountant.

In June 1986, Malcolm Hoenlein was elected Executive Vice Chairman of the Conference of Presidents of Major American Jewish Organizations, the coordinating body on international Jewish concerns for 50 national Jewish organizations. Previously, he served as the founding Executive Director of the Jewish Community Relations Council of Greater New York , the central coordinating agency for Jewish organizations in the metropolitan New York area. Prior to that, he was the founding Executive Director of the Greater New York Conference on Soviet Jewry. Malcolm Hoenlein received his B.A. in Political Science from Temple University and his Masters degree from the University of Pennsylvania?s Department of International Relations, where he completed his doctoral course work. A National Defense Fellow in the University?s Near East Center , Mr. Hoenlein taught International Relations in the Political Science Department and served as a Middle East specialist at the Foreign Policy Research Institute. In addition, he served on the editorial staff of ORBIS, the Journal of International Affairs. Mr. Hoenlein has traveled throughout the world meeting with world leaders and Jewish communities. He has written and lectured across the US and abroad on international relations, Israel and Middle East affairs, Soviet and World Jewry, terrorism, the American Jewish community, and intergroup relations. Mr. Hoenlein serves as an advisor to many public officials and is frequently consulted on public policy issues. He appears regularly in the media. Mr. Hoenlein has been the recipient of many awards and tributes. Among recent honors, he was conferred a Doctorate of Humane Letters (Honoris Causa) by Yeshiva University and a Doctorate of Laws (Honoris Causa) from Touro College and was honored by, among others, State of Israel Bonds for his ?valiant and extraordinary service to Israel and the Jewish people,? the Private Sector Initiative Award from President Ronald Reagan, American ORT honored him with a special ?Man of the Millennium? Tribute, the first Quittman Award for Jewish Professional Excellence, the Defender of Jerusalem Award, Millender Fellow at Brandeis University, Fellow of the Jerusalem College of Technology, the Jack D. Weiler Award for Jewish Communal Service, and the Union of Orthodox Jewish Congregations National Service Award. Mr. Hoenlein played a key role in organizing the massive National Solidarity Rally for Israel in Washington, DC in 2002. The Forward listed him as the most influential Jewish leader.

Wyche Fowler, Jr., 68, has served on our Board of Directors since November 2006. Senator Fowler served for 16 years in the United States Congress representing the state of Georgia, including service in the United States Senate from 1987 to 1993. Following his service as a Senator, Senator Fowler served as the U.S. Ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. He received his B.A. in English from Davidson College, a J.D. from Emory University and honorary degrees from Hofstra University, Davidson College and Morris Brown College. Prior to his election to Congress, he practiced law in Atlanta, Georgia for eight years. He is currently engaged in an international business and law practice and serves as Chairman of the Board of the Middle East Institute, a non-profit research foundation in Washington, D.C. Mr. Fowler also serves on the board of directors of Shubert Theaters, the Shubert Foundation, Brandywine Realty Trust and ZIOPHARM Oncology, Inc.